YL242 / MediLink - LARVOL DELTA

Preclinical development of YL242, a non-internalized antibody-drug conjugate (ADC) targeting soluble VEGF for treatment of solid tumors (AACR 2025) - "In summary, VEGF-targeted ADC YL242 synergistically combines both antitumor activity of cytotoxic payload and anti-angiogenesis effect of antibody and demonstrated both antitumor efficacy and safety. Consequently, YL242 holds promise for further development in the treatment of cancer patients."

ADC • Preclinical • Oncology • Solid Tumor

A Study of YL242 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=424 | Recruiting | Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

First-in-human • Monotherapy • New P1/2 trial • Solid Tumor

Yilian Biopharmaceuticals’ YL242 project obtains FDA clinical trial approval (Yilian Biopharma Press Release) - "Suzhou Yilian Biopharmaceutical Co., Ltd...announced that its independently developed antibody-drug conjugate YL242 has obtained implicit approval of the U.S. Food and Drug Administration (FDA) for the new drug clinical trial application (IND), and the IND in China has been formally accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration."

IND • New trial • Oncology